MX2022011289A - Porcion de direccionamiento a cd22 para el tratamiento de leucemia linfoblastica aguda de celulas b (b-all). - Google Patents

Porcion de direccionamiento a cd22 para el tratamiento de leucemia linfoblastica aguda de celulas b (b-all).

Info

Publication number
MX2022011289A
MX2022011289A MX2022011289A MX2022011289A MX2022011289A MX 2022011289 A MX2022011289 A MX 2022011289A MX 2022011289 A MX2022011289 A MX 2022011289A MX 2022011289 A MX2022011289 A MX 2022011289A MX 2022011289 A MX2022011289 A MX 2022011289A
Authority
MX
Mexico
Prior art keywords
treatment
lymphoblastic leukemia
acute lymphoblastic
cell acute
targeting
Prior art date
Application number
MX2022011289A
Other languages
English (en)
Inventor
Buján Pablo Menéndez
Hernández Talía Velasco
Samanta Romina ZANETI
Rocamora Pablo Engel
Martínez Diego Sánchez
Agüera Francisco Gutierrez
Martín Adrián Fernández
Cortés Victor Manuel Díaz
Original Assignee
Fundacio Inst De Recerca Contra La Leucemia Josep Carreras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst De Recerca Contra La Leucemia Josep Carreras filed Critical Fundacio Inst De Recerca Contra La Leucemia Josep Carreras
Publication of MX2022011289A publication Critical patent/MX2022011289A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona agentes terapéuticos para el tratamiento de cánceres positivos a CD22, tal como leucemia linfoblástica aguda de células B (B-ALL). En particular, la presente invención proporciona un anticuerpo monoclonal anti-CD22 cuyo scFv como parte de células T de receptores de antígeno quimérico (CAR) puede dirigirse al primer dominio extracelular de Ig del antígeno CD22, el dominio más alejado de la membrana, para uso en el tratamiento de cánceres positivos a CD22.
MX2022011289A 2020-03-11 2021-03-11 Porcion de direccionamiento a cd22 para el tratamiento de leucemia linfoblastica aguda de celulas b (b-all). MX2022011289A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382175 2020-03-11
PCT/EP2021/056262 WO2021180890A1 (en) 2020-03-11 2021-03-11 Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all)

Publications (1)

Publication Number Publication Date
MX2022011289A true MX2022011289A (es) 2022-12-08

Family

ID=69810766

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011289A MX2022011289A (es) 2020-03-11 2021-03-11 Porcion de direccionamiento a cd22 para el tratamiento de leucemia linfoblastica aguda de celulas b (b-all).

Country Status (8)

Country Link
US (1) US12522666B2 (es)
EP (1) EP4117789A1 (es)
JP (1) JP7545139B2 (es)
CN (1) CN115843255B (es)
AU (1) AU2021233158A1 (es)
CA (1) CA3174638A1 (es)
MX (1) MX2022011289A (es)
WO (1) WO2021180890A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011289A (es) * 2020-03-11 2022-12-08 Fundacio Inst De Recerca Contra La Leucemia Josep Carreras Porcion de direccionamiento a cd22 para el tratamiento de leucemia linfoblastica aguda de celulas b (b-all).
WO2024243189A2 (en) * 2023-05-22 2024-11-28 Board Of Regents, The University Of Texas System Antigen binding proteins targeting pd-1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
PT3560953T (pt) 2014-12-24 2024-03-26 Autolus Ltd Célula
IL303972A (en) * 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
CN109957023A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向cd22的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN108715859B (zh) * 2018-05-31 2021-08-03 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靶向cd22的嵌合抗原受体及其应用
MX2022011289A (es) * 2020-03-11 2022-12-08 Fundacio Inst De Recerca Contra La Leucemia Josep Carreras Porcion de direccionamiento a cd22 para el tratamiento de leucemia linfoblastica aguda de celulas b (b-all).

Also Published As

Publication number Publication date
WO2021180890A1 (en) 2021-09-16
JP7545139B2 (ja) 2024-09-04
EP4117789A1 (en) 2023-01-18
JP2023523682A (ja) 2023-06-07
AU2021233158A1 (en) 2022-09-29
CA3174638A1 (en) 2021-09-16
US20230139885A1 (en) 2023-05-04
US12522666B2 (en) 2026-01-13
CN115843255A (zh) 2023-03-24
CN115843255B (zh) 2026-03-10
AU2021233158A2 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
CO2021010075A2 (es) Receptores de antígenos quiméricos de gprc5d y células que los expresan
MX2022005152A (es) Uso de receptores de antigenos quimericos anti-bcma.
ZA202100391B (en) Ror-1 specific chimeric antigen receptors and uses thereof
MX2022002297A (es) Receptores de citocinas quimericos que comprenden dominios de union al tgf beta.
MX2022011289A (es) Porcion de direccionamiento a cd22 para el tratamiento de leucemia linfoblastica aguda de celulas b (b-all).
MX2021010444A (es) Receptores de citocinas quimericos que tienen un ectodominio de pd-1.
AR117685A1 (es) Antígeno quimérico y receptores de células t y métodos de uso
NI202000036A (es) Anticuerpo específicos para el transcrito semillar a la inmunoglobulina tipo 3 (ilt3) y sus usos.
EP4223269A3 (en) Uses of anti-bcma chimeric antigen receptors
CU20190099A7 (es) Dominio de unión a antígeno anti-trbc1, y receptor de antígeno quimérico, anticuerpo, acoplador biespecífico de células t y conjugado anticuerpo-fármaco que comprenden el mismo
ZA202311718B (en) Muc16 specific chimeric antigen receptors and uses thereof
AR104718A1 (es) Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer
ZA202206438B (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
PE20170125A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
CO2022000705A2 (es) Receptor de antígeno quimérico (car) anti-hk2
WO2021048564A3 (en) Antigen-binding domain
MX2021003168A (es) Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.
CL2024002066A1 (es) Receptores de antígeno muc16 quiméricos
MX2021012820A (es) Receptores de antigenos quimericos resistentes a rituximab y usos de estos.
EP4272837A3 (en) Car t-cells against bcma for the treatment of multiple myeloma
PH12019550203A1 (en) Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
BR112023022133A2 (pt) Uso de um anticorpo anti-cd19 para tratar miastenia gravis
MX2021009744A (es) Composiciones de anticuerpos lym-1 y lym-2 y constructos car mejorados.
WO2025088223A3 (en) Car t-cells against cd79b for the treatment of non-hodgkin lymphoma
AR119469A1 (es) Receptor de antígeno quimérico anti-hk2 (car)